Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073 [PMID: 32258077 DOI: 10.12998/wjcc.v8.i6.1065]
Corresponding Author of This Article
Zhao-Dong Zhong, MD, Doctor, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Hankou District, Wuhan 430030, Hubei Province, China. whxhzzd008@126.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073 [PMID: 32258077 DOI: 10.12998/wjcc.v8.i6.1065]
World J Clin Cases. Mar 26, 2020; 8(6): 1065-1073 Published online Mar 26, 2020. doi: 10.12998/wjcc.v8.i6.1065
Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients
Si-Hua Dang, Qin Liu, Rong Xie, Na Shen, Shu Zhou, Wei Shi, Wen Liu, Ping Zou, Yong You, Zhao-Dong Zhong
Si-Hua Dang, Rong Xie, Na Shen, Shu Zhou, Wei Shi, Wen Liu, Ping Zou, Yong You, Zhao-Dong Zhong, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Si-Hua Dang, Department of Oncology, Luohe Central Hospital, Luohe 462300, Henan Province, China
Qin Liu, Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Dang SH and Liu Q contributed equally to this article, conceived of and coordinated the study, designed, performed, and analyzed the experiments, and wrote the paper; Xie R, Shen N, Zhou S, Shi W, Liu W, and Zou P performed the data collection and data analysis, and revised the paper; You Y and Zhong ZD designed the study, carried out the data collection and data analysis, and revised the paper; All authors reviewed the results and approved the final version of the manuscript.
Institutional review board statement: This study was approved by the institutional review board of the Union Hospital of Tongji Medical College.
Informed consent statement: Waived because of the retrospective study design.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Data sharing statement: The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Zhao-Dong Zhong, MD, Doctor, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Hankou District, Wuhan 430030, Hubei Province, China. whxhzzd008@126.com
Received: November 22, 2019 Peer-review started: November 22, 2019 First decision: December 12, 2019 Revised: February 19, 2020 Accepted: February 28, 2020 Article in press: February 28, 2020 Published online: March 26, 2020 Processing time: 124 Days and 13.7 Hours
Core Tip
Core tip: This study aimed to investigate the effect and safety of ruxolitinib add-on in the treatment of patients with steroid-refractory (SR) acute (a) and chronic (c) graft-vs-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. An important finding of this retrospective case series was that the use of ruxolitinib as a salvage therapy for SR-GVHD resulted in an overall response rate of 100% in patients with SR-aGVHD (complete response: 80%) and 82.1% in patients with SR-cGVHD (complete response: 10.7%). In addition, this was achieved with a lower dose (5-10 mg/d) of ruxolitinib than previous reports, indicating that the dose of ruxolitinib could be lowered when used in combination with antifungal drugs (CYP2C9/CYP3A4 inhibitors).
